STOCKWATCH: JPM notes
This article was originally published in Scrip
As the sun shone and sunglasses stalls came out to greet people in T-shirts, flip flops and shorts, one of the paradoxes of last week’s JP Morgan conference was that the holiday ice rink in Union Square was still doing a brisk trade.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.